

Feasibility and Pilot Efficacy Results From the Multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Randomized Controlled Trial

Richard S. E. Keefe, PhD; Sophia Vinogradov, MD; Alice Medalia, PhD; Peter F. Buckley, MD; Stanley N. Caroff, MD; Deepak C. D'Souza, MD; Phillip D. Harvey, PhD; Karen A. Graham, MD; Robert M. Hamer, PhD; Stephen M. Marder, MD; Del D. Miller, PharmD, MD; Stephen J. Olson, MD; Jayendra K. Patel, MD; Dawn Velligan, PhD; Trina M. Walker, RN; Adam J. Haim, PhD; and T. Scott Stroup, MD

ABSTRACT

Background: The true benefit of pharmacologic intervention to improve cognition in schizophrenia may not be evident without regular cognitive enrichment. Clinical trials assessing the neurocognitive effects of new medications may require engagement in cognitive remediation exercises to stimulate the benefit potential. However, the feasibility of large-scale multisite studies using cognitive remediation at clinical trials sites has not been established.

Method: 53 adult patients with *DSM-IV* schizophrenia from 9 university-affiliated sites were randomized to a cognitive remediation condition that included the Posit Science Brain Fitness auditory training program with weekly Neuropsychological and Educational Approach to Remediation (NEAR) "bridging groups" or a control condition of computer games and weekly healthy lifestyles groups. Patients were expected to complete 3 to 5 one-hour sessions weekly for 40 sessions or 12 weeks, whichever came first. The primary outcomes were feasibility results as measured by rate of enrollment, retention, and completion rate of primary outcome measures. The study was conducted from July 2009 through January 2010.

Results: During a 3-month enrollment period, 53 (of a projected 54) patients were enrolled, and 41 (77%) met criteria for study completion. Thirty-one patients completed all 40 sessions, and all patients completed all primary outcome measures. Preliminary efficacy results indicated that, after 20 sessions, patients in the cognitive remediation condition demonstrated mean MATRICS Consensus Cognitive Battery composite score improvements that were 3.7 (95% CI, 0.05–7.34) T-score points greater than in patients in the computer-games control group ($F_{1,46} = 4.16, P = .047$). At the end of treatment, a trend favoring cognitive remediation was not statistically significant ($F_{1,47} = 2.26, P = .14$).

Conclusion: Multisite clinical trials of cognitive remediation using the Posit Science Brain Fitness auditory training program with the NEAR method of weekly bridging groups at traditional clinical sites appear to be feasible.

Trial Registration: ClinicalTrials.gov identifier: NCT00930150

J Clin Psychiatry 2012;73(7):1016–1022

© Copyright 2012 Physicians Postgraduate Press, Inc.

See also Commentary on page 1023.

Submitted: April 26, 2011; accepted December 15, 2011.

Online ahead of print: May 15, 2012 (doi:10.4088/JCP.11m07100).

Corresponding author: Richard S. E. Keefe, PhD, Box 3270, Duke University Medical Center, Durham, NC 27710 (richard.keefe@duke.edu).

Neurocognitive impairment affects almost all patients with schizophrenia,¹ ranges from moderate to severe,² and is strongly correlated with functional outcomes.^{3,4} Current antipsychotic treatment does little to improve cognitive impairment.^{5,6} While several studies are ongoing to explore new treatments for cognitive impairment in schizophrenia, no pharmacologic approaches to improve cognition have yet been successful.^{7–9}

Many patients who enroll in pharmacologic enhancement studies have little daily cognitive stimulation. It is possible that experimental pharmacologic interventions offer minimal or no benefit when patients are evaluated in this context. Analogous to the need for physical exercise in an individual who takes steroids to increase muscle mass, schizophrenia patients in pharmacologic intervention trials may require systematic cognitive training to "exercise" any newly found cognitive potential that they may have acquired from drug treatment.¹⁰

Cognitive remediation has been defined as "a behavioral training based intervention that aims to improve cognitive processes (attention, memory, executive function, social cognition or metacognition) with the goal of durability and generalization" (Wykes T, Cognitive Remediation Experts Workshop, verbal communication, April 2010). This area of work is rapidly evolving with many methodological barriers and potential advances. Cognitive remediation may provide an excellent platform for enriching the cognitive environment of patients engaged in pharmacologic trials to improve cognition.¹¹ Several studies and meta-analyses suggest that cognitive remediation produces medium effect size improvements in cognitive performance and, when combined with psychiatric rehabilitation, also improves functional outcomes.^{12,13} Patients find these programs to be enjoyable and engaging, and they have been linked with increases in participant self-esteem.¹⁴ Previous cognitive remediation trials have reported significant effects,^{12–14} including those studies that have tested the Posit Science auditory module compared to a control condition of computer games.^{15–17}

Ongoing treatment with cognitive remediation may thus provide schizophrenia patients with the necessary cognitive enrichment and motivation to demonstrate the true potential of effective cognitive enhancement with pharmacologic intervention. However, it is not clear whether a cognitive remediation intervention could be successfully employed in

- Cognitive remediation interventions improve cognitive performance in patients with schizophrenia.
- These interventions can be implemented at research and clinical sites without previous experience or specific expertise.
- Clinical trials assessing the efficacy of new drugs targeting cognition in schizophrenia can feasibly use cognitive remediation to enrich the cognitive lives of patients in these trials.

the large multisite clinical trials that are designed to assess drug safety and efficacy. Most of the cognitive remediation studies performed to date in patients with schizophrenia have been implemented at single sites with highly trained research personnel and methods developed at those sites; thus, the generalizability of these methods to research sites with limited cognitive remediation experience is not well established.

The goal of this study was to assess the feasibility of implementing a cognitive remediation program in a network of sites that do not specialize in this area of research, with the following aims: (1) determine the feasibility of training staff to provide evidence-based cognitive remediation to patients with schizophrenia in a set of clinical sites without substantial cognitive remediation experience but with clinical trial experience; (2) determine the feasibility of conducting a controlled, randomized clinical trial to test the effectiveness of cognitive remediation for individuals with schizophrenia or schizoaffective disorder; and (3) determine whether a cognitive remediation protocol can be implemented with a high level of protocol adherence by sites and with low attrition and good treatment adherence by patients. We also provide preliminary multisite efficacy data on the effect of a cognitive remediation program on neurocognition and related outcomes.

METHOD

Patients and Sites

Nine sites from the Schizophrenia Trials Network, which was originally created to conduct the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, were involved in the study (ClinicalTrials.gov identifier: NCT00930150). Seven of the sites had no previous experience with cognitive remediation trials. Each site was asked to enroll 6 patients with chronic *DSM-IV* schizophrenia over the course of 3 months, estimating a reasonable rate of recruitment for a large-scale efficacy trial. A total of 53 patients were entered into the study. Patients were required to fit the following criteria: be 18–55 years of age; have Positive and Negative Syndrome Scale (PANSS)¹⁸ hallucinatory behavior, unusual thought content, and conceptual disorganization ratings no greater than moderately severe (≤ 5); have learned English before age 12; be able to complete

the MATRICS Consensus Cognitive Battery (MCCB)¹⁹ at the baseline assessment; obtain a raw score of 37 or greater on the Wide Range Achievement Test, reading subtest, 3rd edition,²⁰ to establish minimum reading level (6th grade) and estimated premorbid intelligence quotient; and be able to state specific goals relevant to the intervention that they would like to achieve. Patients were excluded from participating in the study if they met any of the following criteria: psychiatric hospitalization in the 8 weeks prior to randomization, adjustments in antipsychotic treatment in the 4 weeks prior to randomization, current regular use of an anticholinergic medication, *DSM-IV* diagnosis of alcohol or substance (other than nicotine) abuse within the last month or dependence within the last 6 months, and history of mental retardation or pervasive developmental disorder or other neurologic disorder. Institutional review board approval for the protocol was obtained at all sites. Informed consent was obtained for all patients.

Treatments

The program was based upon suggestions from an National Institute of Mental Health Working Group on multisite cognitive remediation methods.¹⁰ It was designed to be completed over 8 weeks and consisted of 40 hours of computerized cognitive remediation training or control computer games and 5 hours of group sessions. Patients were permitted up to 12 weeks to complete the 40 hours of training. For each of the 3 assessment visits, patients received \$20 to help compensate for effort and for transportation costs. To help pay for travel to receive cognitive remediation or the control intervention for this research study, patients received limited reimbursement (\$5) for transportation costs.

Cognitive Remediation

Posit Science Brain Fitness auditory training. Patients randomized to the cognitive remediation group received the computerized Posit Science Brain Fitness auditory training program, which has demonstrated successful results in schizophrenia.^{15,16} This program targets cognitive ability hierarchically in an adaptive design, with repeated exercises aimed at lower cognitive levels (eg, auditory perception) before advancing to more complex cognitive constructs such as verbal memory.²¹ Performance is rewarded through the use of novel and amusing visual and auditory embellishments, animated graphics, and an accumulation of points for each successful trial.

Bridging groups. To help patients apply their cognitive skills to their everyday functioning, study patients receiving the auditory training cognitive remediation program also attended “bridging groups” that met every week. The goals of these groups were to teach patients how to apply newly acquired cognitive skills to everyday tasks, promote group identity, and promote socialization, as conducted in the Neuropsychological Educational Approach to Remediation (or NEAR) program.²² These bridging groups were very structured, with detailed manuals.

Control Intervention

A control condition was included to determine the effects of the randomization process and randomized treatment on recruitment, informed consent, retention, patient burden, and maintenance of blinded conditions for assessing outcomes and to control for nonspecific treatment effects, such as supportive interactions with research personnel, reimbursements, experience with computers and computer activities, and general engagement of attentional systems.

Computer games. Patients in this condition played enjoyable computer games for the same number of hours as active training patients and received the same amount of contact with personnel as the experimental group. Patients used 10 computerized games selected and studied by Fisher et al.¹⁵

Healthy lifestyles groups. To control for possible general benefits of group participation, study patients receiving the control condition received a healthy lifestyles group developed by Ganguli.²³

Clinician Training

Clinicians who performed the cognitive remediation and control conditions were all qualified as master's-level mental health therapists, or, if they did not have a master's degree, they had at least 3 years of experience running psychosocial groups for people with persistent and severe mental illness. All clinicians were trained together at a day-long in-person training by a representative from Posit Science Corporation and by one of the authors (A.M.). Subsequent group phone supervision was provided monthly by A.M. to assure treatment fidelity across sites. There was no turnover in clinicians during the study.

Randomization and Blinding

Each site randomly assigned 3 patients to cognitive remediation and 3 patients to the computer games control group. Treatments were open-label, but cognitive testers were blinded to treatment assignments. The success of the blinding procedures was evaluated as an outcome measure in this feasibility study.

Feasibility Outcomes

The key indicators to evaluate the feasibility of this study were rate of enrollment per site and overall, retention of patients in the trial, number of sessions completed during the course of the trial, blinding effectiveness, and completion rate of primary outcome measures

Key Efficacy Outcomes

All efficacy outcomes were evaluated at midpoint (after 20 hours of participation in the assigned intervention, no more than 6 weeks postrandomization) and end of study (after 40 hours or 12 weeks of participation in the assigned intervention, whichever came first).

Auditory frequency discrimination task. The most basic of the auditory training exercises requires users to make gradually more difficult distinctions between frequency

modulation “sweeps” of auditory stimuli that increase or decrease in frequency as the sweeps become progressively faster and are separated by shorter interstimulus intervals. As a positive control for task learning, patients' performance on this task was determined in both treatment conditions. The outcome measures for this task were the shortest stimulus duration and interstimulus interval (which were equal to each other) for trials in which patients were able to perform the task at 67% accuracy.¹⁵

MCCB. The MCCB was used to assess cognitive functioning in each of 7 domains. T-scores were created for each cognitive domain and an overall composite score, which was the primary efficacy outcome.

Secondary Outcomes

The University of California San Diego Performance-Based Skills Assessment, 2nd Edition,²⁴ is a performance-based measure of the extent to which patients are capable of performing specific functional living skills such as household chores, communication, finance, transportation, and planning of recreational activities.²⁵

The Cognitive Assessment Interview (CAI)²⁶ is a 10-item interview-based measure of cognitive function that incorporates ratings from 3 primary sources—subject, informant, and interviewer. The presence of an informant interview was requested but not required.

Additional measures included the PANSS,²⁷ which was the primary assessment instrument for psychopathology; the Clinical Global Impressions-Severity of illness scale²⁸ for rating severity of psychopathology; the Specific Levels of Functioning scale²⁹ for measuring function in the areas of self-maintenance, social functioning, and community living skills; the Rosenberg Self-Esteem scale³⁰; the Intrinsic Motivation Inventory-Schizophrenia Research scale³¹; and the Perceived Competency Scale.³² The overall study methodology quality was measured with the Clinical Trial Assessment Measure, a 15-item, reliable and valid scale (range = 0–100) of trial methodology for psychological treatment studies.³³

Data Analysis

The primary outcome for this trial was determination of the feasibility of conducting a multisite trial using cognitive remediation. Additional key outcomes were the completion rate of the primary and secondary outcome measures.

Exploratory efficacy analyses assessed whether there were significant changes after 20 sessions, which was the midpoint of the treatment schedule, and at endpoint, beyond expected practice effects (0.2 standard deviations [SDs]) in the composite scores from the MCCB.³⁴ The data were analyzed using a mixed-model approach to repeated measures, using change from baseline to each postbaseline time point as the response, baseline as a covariate, and treatment, visit, and treatment-by-visit interactions as the predictors. Exploratory analyses were performed using the same methodology for all MCCB subscales and the other outcomes.

RESULTS

Demographic and clinical characteristics are described in Table 1. The 2 treatment groups did not differ at baseline on any of the 17 clinical or cognitive outcome measures except the Perceived Competency Scale ($P < .02$), which would not have been statistically significant if corrected for multiple comparisons. The baseline, session 20, and end-of-treatment values for all outcomes are presented in Table 2.

Feasibility

The CONSORT flow diagram (Figure 1) describes the sample sizes for each treatment arm. Our stated goal was for 8 of 9 chosen sites to participate in the trial and for each site to enroll 6 patients. All 9 sites participated, and 8 of them enrolled 6 patients, with 1 site enrolling 5. We defined study completion as 24 or more sessions completed in 12 weeks and no fewer than 8 sessions within a 4-week period, with a stated feasibility goal of 75% study completion. Of the 53 patients in the study, 47 completed all key efficacy endpoints, 25 in the cognitive remediation group and 22 in the computer games control group. Thirty-one patients (16 in the cognitive remediation condition and 15 in the control condition) completed all 40 sessions, and 10 patients completed between 24 and 40 sessions in 12 weeks of treatment. Thus, a total of 41 patients (77%) met criteria for study completion. Of the 16 patients completing fewer than 40 sessions, 9 patients in the cognitive remediation group completed a mean of 24.1 (SD = 7.50) sessions, and 7 patients in the control group completed a mean of 30.0 (SD = 5.42) sessions in 12 weeks. Of the 6 patients who did not complete the study, 2 were not willing to maintain the time commitment, and 4 withdrew for unspecified reasons.

Study Methodology Quality

The overall study quality as rated by the Clinical Trials Assessment Measure was 87, which is equal to the top score given by Wykes et al¹⁷ in their review of 40 cognitive remediation trials, for which the mean Clinical Trials Assessment Measure rating was 57.4 (SD = 12.3).

Outcome Measure Completion

All patients completed all MCCB tests at all time points. No more than 3 patients had missing data on any of the secondary outcome measures, including all 3 visits. All patients had interviewer ratings for the CAI; informant interview data were missing for 8, 13, and 14 patients at baseline, 20 sessions, and end of study, respectively, for the cognitive remediation group and for 10, 11, and 12 patients at those time points for the control group.

Blinding Effectiveness

The blinding procedures were very effective. All cognitive testers completed a form asking them to estimate whether they were unblinded about patients' treatment condition. In 2 cases, 1 in each treatment condition, testers estimated "definite" unblinding, and both reports were correct. In 15 additional cases, testers estimated "possible" unblinding.

Table 1. Demographic Data for the Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Pilot Study

Variable	Data (N = 53)
Age, mean (SD), y	37.00 (10.27)
Total years of education, mean (SD)	13.49 (2.24)
WRAT reading score, mean (SD)	48.50 (5.31)
Patient education level, n	
≥ High school	46
< High school	7
Sex, n	
Male	39
Female	14
Race, n	
White	30
Black	18
Other	5
Marital status, n	
Married	4
Previously married ^a	8
Never married	41
Living status, n	
Independent living	42
Minimally structured living	6
Moderately structured living	5

^aIncludes separated, divorced, and widowed.

Abbreviation: WRAT = Wide Range Achievement Test.

However, less than 50% of those estimates were correct, which was less than chance. In 9 cases, testers were reasonably certain that a patient was receiving the cognitive remediation, but in only 4 of those cases was the tester correct. In 6 cases, the tester was reasonably certain that a patient was receiving the control intervention, but in only 3 of those cases was the tester correct.

Efficacy Analyses

Auditory frequency discrimination. Patients receiving the cognitive remediation intervention had substantial mean improvements on the auditory discrimination task (see Table 2) that were significantly greater than in patients in the control condition, who did not improve during the course of the study. This finding indicates that patients in the cognitive remediation group significantly improved their psychophysical efficiency in discriminating rapidly presented auditory frequency modulation sweeps, while control condition patients did not.

MCCB. After 20 weeks, patients receiving the cognitive remediation treatment condition had MCCB composite scores (adjusted for baseline) of 32.74 compared to 29.04 for patients receiving the control condition ($F_{1,46} = 4.16, P = .047$) (see Table 2). This mean change of 3.7 T-score points had a 95% CI of 0.05–7.34. At the end of treatment, patients receiving cognitive remediation had MCCB composite scores (adjusted for baseline) of 32.38 compared to 29.65 for those in the control condition ($F_{1,47} = 2.26, P = .14$; mean change = 2.73; 95% CI, 0.93–6.39). Post hoc analyses suggested that the MCCB domains contributing most strongly to improvement in the cognitive remediation group were verbal learning ($P = .0335$) and social cognition ($P = .0631$) at the 20-session point and reasoning and problem-solving at the end of the study ($P = .0877$). In patients receiving cognitive remediation, improvement in the auditory frequency

Table 2. Baseline Measurements and Treatment Effects for Cognitive, Functional, and Clinical Outcomes by Treatment Group

Measure	Baseline Mean (SD)		20-Session Least-Squares Mean (SEM) ^a		End-of-Treatment Least-Squares Mean (SEM) ^a		Change From Baseline by Treatment Group, P Value ^b	
	Control Group	Treatment Group	Control Group	Treatment Group	Control Group	Treatment Group	20	End of
							Sessions	Treatment
MATRICES Consensus Cognitive Battery composite	27.31 (11.49)	27.92 (11.68)	29.04 (1.31)	32.74 (1.25)	29.65 (1.32)	32.38 (1.25)	.0470	.1398
Speed of processing	33.42 (13.65)	35.65 (11.02)	37.99 (1.31)	37.40 (1.27)	38.07 (1.26)	38.87 (1.19)	.7500	.6488
Attention vigilance	34.54 (12.11)	35.31 (12.68)	35.48 (1.73)	37.88 (1.66)	36.09 (1.86)	38.83 (1.75)	.3241	.2889
Working memory	36.50 (12.84)	35.77 (12.03)	37.49 (1.53)	39.03 (1.49)	38.67 (1.29)	38.97 (1.23)	.4755	.8673
Verbal learning	35.62 (6.89)	34.77 (6.29)	34.67 (1.21)	38.38 (1.17)	35.59 (1.30)	37.32 (1.22)	.0335	.3369
Visual learning	33.35 (12.15)	32.15 (13.14)	35.28 (2.23)	37.02 (2.16)	34.06 (1.98)	35.87 (1.88)	.5774	.5103
Reason and problem solving	39.08 (8.86)	40.46 (10.12)	39.66 (1.49)	42.57 (1.44)	40.80 (1.54)	44.48 (1.45)	.1673	.0877
Social cognition	39.35 (11.20)	40.69 (10.54)	38.84 (1.89)	43.85 (1.83)	39.58 (1.63)	39.93 (1.55)	.0631	.8759
Auditory frequency discrimination task	158.30 (125.10)	206.70 (202.30)	164.69 (18.08)	70.11 (17.22)	172.37 (20.48)	71.49 (19.49)	.0005	.0009
Cognitive Assessment Interview	3.31 (1.26)	3.26 (0.94)	3.18 (0.19)	3.01 (0.18)	3.31 (0.18)	3.07 (0.17)	.5229	.3574
Rosenberg Self-Esteem scale	19.65 (5.42)	20.33 (5.02)	19.33 (0.80)	21.15 (0.75)	20.67 (1.00)	21.36 (0.91)	.1029	.6153
Specific Levels of Functioning	127.50 (13.82)	127.70 (13.22)	... ^c	... ^c	126.22 (14.28)	129.35 (12.38)	... ^c	.4206
Intrinsic Motivation Inventory	104.00 (25.06)	116.70 (20.49)	115.49 (3.79)	112.20 (3.69)	118.38 (2.99)	112.19 (2.85)	.5417	.1480
Perceived Competency Scale	20.72 (6.47)	24.37 (4.83)	23.69 (0.93)	23.04 (0.91)	23.72 (1.11)	23.36 (1.04)	.6238	.8148
University of California San Diego Performance-Based Skills Assessment	66.40 (11.51)	65.19 (12.68)	... ^c	... ^c	68.22 (9.43)	66.50 (13.10)	... ^c	.5500
Clinical Global Impressions-Severity of Illness scale	3.62 (0.75)	3.41 (0.84)	... ^c	... ^c	3.61 (0.94)	3.12 (0.86)	... ^c	.2335
Positive and Negative Syndrome Scale	56.69 (15.35)	55.70 (13.75)	... ^c	... ^c	59.91 (15.97)	54.08 (15.75)	... ^c	.3389


^aLeast-squares mean values from mixed-model analysis corrected for baseline values for each analysis.

^bBolded P values indicate significance.

^cThese tests were not performed during the 20-session assessment but only at baseline and end of study.

Abbreviations: SD = standard deviation, SEM = standard error of the mean.

Figure 1. Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Pilot Study CONSORT Flow Diagram



discrimination task was not correlated with changes in the MCCB composite score or its component domains (all *r* statistics < 0.31; all *P* values > .14).

Additional outcomes. There were no significant treatment-related differences on any of the secondary outcome measures (see Table 2).

DISCUSSION

This study assessed the feasibility of conducting a randomized and blinded multisite trial using a computerized auditory cognitive remediation intervention with weekly bridging groups compared to a control condition of

computer games paired with healthy lifestyles weekly group meetings. The burden on patient treatment and assessment was considerable, with a 40-session target over the course of 8 to 12 weeks and a large battery of clinical and cognitive assessments at baseline, midpoint, and endpoint. In terms of training, enrollment, patient engagement, and study completion, multisite trials of cognitive remediation using these active and control interventions appear to be feasible, supporting large-scale efficacy trials of cognitive remediation and the use of cognitive remediation as a potential platform for large-scale drug trials. All sites were able to train testers and cognitive remediation specialists to the satisfaction of the intervention developers. Further, there were no missing cognitive measures on the MCCB and almost no missing data on the clinical outcomes. The retention rate was very high, with 25 of 27 patients (93%) completing the cognitive remediation arm of the study. This rate is comparable to previously published single-site studies using similar methodologies^{13,15} and the average retention rate of 89% reported in the Wykes et al meta-analysis of 40 studies.¹⁷ This retention rate is also consistent with similarly sized government-funded trials assessing the effects of pharmacologic interventions to improve cognition in schizophrenia.⁷ However, only 77% of patients met criteria for study completion (24 completed intervention sessions). Since a significant minority of patients may have difficulty attending daily cognitive remediation sessions, sites and the patients they enroll may need to be screened for their commitment to the regularity of intervention sessions prior to entry into a study. The sites in this study were academic medical centers and included patients that were slightly younger than many completed pharmacologic trials,³⁵ and it is not clear whether such encouraging results would be replicated in nonacademic industry trials with older patients. It is also not clear how these results would generalize to other cognitive remediation interventions. However, it appears that the requirement of this cognitive remediation intervention—or a similar one—in a drug trial for cognition in schizophrenia is unlikely to significantly affect recruitment, retention, or the completion of the study data set.

Although the intention of this study was not to test the efficacy of the cognitive remediation intervention, it is noteworthy that patients randomized to this condition demonstrated significant improvement in the Food and Drug Administration–recommended cognitive outcome, the MCCB composite score, after 20 sessions of treatment. This amount of benefit is consistent with previous single-site studies,¹⁵ similar to that obtained by McGurk et al¹² with a different cognitive remediation package, and within 0.1 effect-size units of the mean improvement reported in the recent meta-analysis of Wykes et al.¹⁷ However, in the current study, there was no additional benefit to the MCCB at the endpoint. Due to an enrollment and study completion deadline for this project, patients were given only 12 weeks to complete the 40 sessions, which may not have been sufficient time to gain the maximal benefit of treatment. It

is possible that since 9 of the 25 patients did not receive the entire 40-session intervention, the efficacy of the cognitive remediation was reduced. Patients in the auditory training cognitive remediation group demonstrated robust improvement in the auditory frequency discrimination task at 20 sessions but showed no additional improvement by the end of the study. Little is known about the ideal or minimal dose, frequency, and time course of cognitive remediation treatment response, which may differ across individuals,^{10,36–38} and these issues need to be examined in future studies.

Because this trial was a feasibility and pilot study, it used a small sample size. However, the effect size for cognitive improvement with the auditory training intervention coupled with NEAR bridging groups is consistent with potential significant benefit for patients, given sufficient statistical power to test this hypothesis. These results and the clear feasibility of the study design in a multisite trial provide positive proof-of-concept, empirical evidence that 2 new directions in clinical trial design are possible and worthy of investigation. First, the results suggest that a large well-powered multisite trial for assessing the true efficacy of cognitive remediation interventions is feasible. Further, the results suggest that drug trials that aim to provide an enriched cognitive environment for patients can successfully implement cognitive remediation across multiple sites that have no prior experience with this intervention.

Author affiliations: Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina (Dr Keefe and Ms Walker); Department of Psychiatry, University of California San Francisco (Dr Vinogradov); Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York (Drs Medalia and Stroup); Department of Psychiatry, Medical College of Georgia, Augusta (Dr Buckley); Department of Psychiatry, Veterans Affairs (VA) Medical Center, University of Pennsylvania School of Medicine, Philadelphia (Dr Caroff); Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut (Dr D'Souza); Department of Psychiatry, University of Miami Miller School of Medicine, Miami VA Medical Center, Florida (Dr Harvey); Departments of Psychiatry and Biostatistics, University of North Carolina at Chapel Hill (Drs Graham and Hamer); Department of Psychiatry, Semel Institute at the University of California Los Angeles, and VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, California (Dr Marder); Department of Psychiatry, University of Iowa, Iowa City (Dr Miller); Department of Psychiatry, University of Minnesota, Minneapolis (Dr Olson); Department of Psychiatry, University of Massachusetts Medical School, Worcester (Dr Patel); Department of Psychiatry, University of Texas Health Science Center at San Antonio (Dr Velligan); and Division of Services and Intervention Research, National Institute of Mental Health (NIMH), Bethesda, Maryland (Dr Haim).

Potential conflicts of interest: Dr Keefe has received research funding from the Department of Veterans Affairs, GlaxoSmithKline, NIMH, Novartis, PsychoGenics, Research Foundation for Mental Hygiene, Singapore Medical Research Council, and Allon; has received unrestricted educational funding from AstraZeneca; has been a consultant for Abbott, Amgen, Astellas, BiolineRx, BrainCells, Bristol-Myers Squibb, CHDI Foundation, Cypress Bioscience, Eli Lilly, EnVivo, Lundbeck, Memory, Merck, NeuroSearch, Orion, Otsuka, Pfizer, Roche, Sanofi-Aventis, Shire, Solvay, Sunovion, and Takeda; has received royalties for the Brief Assessment of Cognition in Schizophrenia (BACS) and the MATRICS Battery (BACS Symbol Coding); and is a shareholder in NeuroCog Trials (Duke University holds the copyright for the Schizophrenia Cognition Rating Scale [SCoRS], and licenses are issued by NeuroCog Trials; there is currently no license fee to use the SCoRS). Dr Vinogradov is a paid consultant on a National Institutes

of Health BRDG-SPAN grant to Brain Plasticity Institute, which has commercial interest in the cognitive training software used in this study. **Dr Buckley** has received grant/research support from NIMH, Janssen, Pfizer, and Sepracor and, as a consultant, has received honoraria and expenses from NIMH. **Dr Caroff** has been a consultant for Neurosearch Sweden. **Dr D'Souza** has received grant/research support from Pfizer, Organon, AstraZeneca, and Abbott and has been a consultant for Bristol-Myers Squibb; his spouse owns Pfizer stock related to previous employment. **Dr Harvey** has been a consultant for Abbott, Bristol-Myers Squibb, Cypress Bioscience, EnVivo, Genentech, and Merck. **Dr Marder** has been a consultant or has been a member of the speakers or advisory boards for Pfizer, Roche, Genetec Biosciences, Abbott, Lundbeck, Novartis, and GlaxoSmithKline and is a stock shareholder in MedAvante. **Dr Miller** has received grant/research support from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, and Pfizer and has been a consultant for Otsuka and GlaxoSmithKline. **Drs Medalia, Graham, Hamer, Olson, Patel, Velligan, Haim, and Stroup** and **Ms Walker** report no potential conflicts of interest relative to the subject of this article.

Funding/support: This work was supported by the National Institute of Mental Health (grant number N01 MH900001). Posit Science Corporation, San Francisco, California, provided the Brain Fitness software and facilitated training for its use during the trial without cost.

Previous presentations: Presented at the First Annual Meeting of the Entertainment Software & Cognitive Neurotherapeutics Society (ESCoNS); September 19–20, 2011; San Francisco, California; and at the 48th Annual Meeting of the American College of Neuropsychopharmacology; December 6–10, 2009; Hollywood, Florida.

Acknowledgments: We acknowledge the great contributions of the patients and their families who devoted their time and energy to this research. We also acknowledge the contributions of the staff members at each of the 9 sites: Medical College of Georgia, Augusta; University of Iowa, Iowa City; University of Massachusetts Medical School, Worcester; University of Miami Miller School of Medicine, Florida; University of Minnesota, Minneapolis; University of North Carolina at Chapel Hill; University of Pennsylvania School of Medicine, Philadelphia; University of Texas Health Science Center at San Antonio; and Yale University School of Medicine, New Haven, Connecticut.

REFERENCES

- Keefe RSE, Easley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. *Biol Psychiatry*. 2005;57(6):688–691.
- Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. *Neuropsychology*. 1998;12(3):426–445.
- Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry*. 1996;153(3):321–330.
- Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? *Schizophr Bull*. 2000;26(1):119–136.
- Keefe RSE, Bilder RM, Davis SM, et al; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. *Arch Gen Psychiatry*. 2007;64(6):633–647.
- Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). *Am J Psychiatry*. 2009;166(6):675–682.
- Buchanan RW, Keefe RS, Umbricht D, et al. The FDA-NIMH-MATRICES guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? *Schizophr Bull*. 2011;37(6):1209–1217.
- Kane JM, D'Souza DC, Patkar AA, et al. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2010;71(11):1475–1481.
- Goff D, Hill M, Barch D. The treatment of cognitive impairment in schizophrenia. *Pharmacol Biochem Behav*. 2011;99(2):245–253.
- Keefe RSE, Vinogradov S, Medalia A, et al. Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. *Schizophr Bull*. 2011;37(5):1057–1065.
- Wykes T. Cognitive remediation therapy needs funding. *Nature*. 2010;468(7321):165–166.
- McGurk SR, Mueser KT, Feldman K, et al. Cognitive training for supported employment: 2–3 year outcomes of a randomized controlled trial. *Am J Psychiatry*. 2007a;164(3):437–441.
- McGurk SR, Twamley EW, Sitzler DI, et al. A meta-analysis of cognitive remediation in schizophrenia. *Am J Psychiatry*. 2007b;164(12):1791–1802.
- Wykes T, Reeder C, Corner J, et al. The effects of neurocognitive remediation on executive processing in patients with schizophrenia. *Schizophr Bull*. 1999;25(2):291–307.
- Fisher M, Holland C, Merzenich MM, et al. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. *Am J Psychiatry*. 2009;166(7):805–811.
- Fisher M, Holland C, Subramaniam K, et al. Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later. *Schizophr Bull*. 2010;36(4):869–879.
- Wykes T, Huddy V, Cellard C, et al. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. *Am J Psychiatry*. 2011;168(5):472–485.
- Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13(2):261–276.
- Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. *Am J Psychiatry*. 2008;165(2):203–213.
- Wilkinson GS. *Wide Range Achievement Test 3 Administration Manual*. Wilmington, DE: Wide Range Inc; 1993.
- Mahncke HW, Bronstone A, Merzenich MM. Brain plasticity and functional losses in the aged: scientific bases for a novel intervention. *Prog Brain Res*. 2006;157:81–109.
- Medalia A, Revheim N. In: Herlants T, ed. *Cognitive Remediation for Psychological Disorders: Therapist Guide*. New York, NY: Oxford University Press; 2009.
- Ganguli R. Behavioral therapy for weight loss in patients with schizophrenia. *J Clin Psychiatry*. 2007;68(suppl 4):19–25.
- Patterson TL, Goldman S, McKibbin CL, et al. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. *Schizophr Bull*. 2001;27(2):235–245.
- Green MF, Schooler NR, Kern RS, et al. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. *Am J Psychiatry*. 2011;168(4):400–407.
- Ventura J, Reise SP, Keefe RS, et al. The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. *Schizophr Res*. 2010;121(1–3):24–31.
- Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. *Br J Psychiatry suppl*. 1989;7(7):59–67.
- Guy W. *ECDEU Assessment Manual for Psychopharmacology*. US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976: 218–222.
- Schneider LC, Struening EL. SLOF: a behavioral rating scale for assessing the mentally ill. *Soc Work Res Abstr*. 1983;19(3):9–21.
- Rosenberg M. *Society and the Adolescent Self-Image*. Princeton, NJ: Princeton University Press; 1965.
- Choi J, Mogami T, Medalia A. Intrinsic motivation inventory: an adapted measure for schizophrenia research. *Schizophr Bull*. 2010;36(5):966–976.
- Choi J, Fiszdon JM, Medalia A. Expectancy-value theory in persistence of learning effects in schizophrenia: role of task value and perceived competency. *Schizophr Bull*. 2010;36(5):957–965.
- Tarrier N, Wykes T. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? a cautious or cautionary tale? *Behav Res Ther*. 2004;42(12):1377–1401.
- Keefe RSE, Fox KH, Harvey PD, et al. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. *Schizophr Res*. 2011;125(2–3):161–168.
- Keefe RS, Buchanan RW, Marder SR, et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? [published online ahead of print November 22, 2011]. *Schizophr Bull*.
- Medalia A, Richardson R. What predicts a good response to cognitive remediation interventions? *Schizophr Bull*. 2005;31(4):942–953.
- Choi J, Medalia A. Factors associated with a positive response to cognitive remediation in a community psychiatric sample. *Psychiatr Serv*. 2005;56(5):602–604.
- Twamley EW, Savla GN, Zurhellen CH, et al. Development and pilot testing of a novel compensatory cognitive training intervention for people with psychosis. *Am J Psychiatr Rehabil*. 2008;11(2):144–163.